AYTU — AYTU BIOSCIENCE INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
AYTU FAQ
What is AYTU's P/E ratio?
AYTU BIOSCIENCE INC (AYTU) currently trades at a P/E ratio of 12.13.
What is AYTU's ROE?
AYTU BIOSCIENCE INC reports a Return on Equity (ROE) of -96.90%.
What is AYTU's dividend yield?
AYTU BIOSCIENCE INC offers a dividend yield of 0.00%.
What is AYTU's Deepscope Quality Score?
Deepscope rates AYTU's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AYTU?
Deepscope's AI Timing Score for AYTU is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AYTU belong to?
AYTU BIOSCIENCE INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 2.15
Price
-0.04
(-1.83%)
Day Change
|
|
|---|
AYTU, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.15 |
| PBV / Sector |
0.68 / 2.65
GREAT
|
| Earning Per Share | -3.07 |
| PE / Sector |
12.13 / 24.99
GOOD
|
| PEG or PE/Growth / Sector |
-0.23 / 0.14
|
| Average 1M Daily Value |
0.09 M
GREAT
|
| Average 1W Daily Value |
0.04 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:20 |
| Symbol | AYTU |
| Name | AYTU BIOSCIENCE INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 10.73 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 23.83 / 10,015.19 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Denver Corporate Center III, Denver, CO, United States, 80237
Phone: 720 437 6580
Website: https://aytubio.com
Employees: 82
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google